key: cord-0919197-bic4nplx
authors: Pregelj, Lisette; Hine, Damian C.; Oyola-Lozada, Maria G.; Munro, Trent P.
title: Working hard or hardly working? Regulatory bottlenecks in developing a COVID-19 vaccine
date: 2020-06-13
journal: Trends Biotechnol
DOI: 10.1016/j.tibtech.2020.06.004
sha: 1bf3b4057f2487864ba83b38749b41469695b77f
doc_id: 919197
cord_uid: bic4nplx

Abstract Vaccine solutions rarely reach the public until after an outbreak abates; an Ebola vaccine was approved 5-years after peak outbreak and SARS, MERS, and Zika vaccines are still in clinical development. Despite massive leaps forward in rapid science, other regulatory bottlenecks are hamstringing the global effort for pandemic vaccines.

When an international team of researchers led by Jeremy Farrar from the Wellcome Trust published an article last November in Nature calling for theories and practices underpinning infectious disease epidemiology to keep pace with the translational nature of epidemics in the 21st Century [1] , few thought the next pandemic would come so soon. Yet, when the

December 2019, the scientific community acted swiftly, collaborating intensely across disciplines and sharing new knowledge in a truly open innovation approach to advancing scientific research [2] [3] [4] [5] .

The combined efforts of the scientific community, mobilization of public health resources, increased public and private investment, and a "completely new culture of doing research" [6] accelerated the first novel vaccine candidate through discovery, lead-candidate optimization, pre-clinical development, and into clinical trials within two-months of the outbreak. Four additional candidates entered the clinic within the next month, and 18 more are expected to begin clinical trials by late 2020 [7] .

J o u r n a l P r e -p r o o f

The rapid spread of COVID-19 helps us understand the volume, diversity, and quality of resources mobilized to realize these unprecedented vaccine development speeds, especially when we compare them to the response to other global outbreaks over the last two decades (see Figure 1 ). The first novel vaccine candidate for COVID-19 began clinical trials one-month faster than the first candidate for the H1N1 swine flu epidemic in 2009 (93 days), and three-months faster than the first Ebola vaccine candidate in 2014 (167 days) (see Table S1 ). These vaccine candidates also started clinical trials ahead of their respective outbreak peaks (see Figure 2 ). [8, 9] .

To achieve the Ebola vaccines' five-year clinical program, global regulators from developed countries combined and leveraged their collective expertise to assist the African Vaccine Regulatory Forum, and worked closely with vaccine developer Merck to conduct supporting and pivotal trials when and where the outbreak was underway [10] . This significantly improved the regulatory and ethics timelines in key areas of pre-submission discussions with sponsors and manufacturers, authorization of clinical trials and emergency use of investigational vaccines, and implementation of joint reviews for ethical and regulatory approvals [10, 11] . The leadership of WHO was the cornerstone of this coordinated regulatory response.

While there are ongoing collaborative efforts around the harmonization of regulatory frameworks in pharmaceuticals and medical devices, the ability to coordinate cross-national regulatory responses in times of crises remains a sticking point. There is ongoing debate about how long a novel COVID-19 vaccine will really take to advance through trials, achieve regulatory approval across multiple jurisdictions, and be manufactured and distributed at the required scale to impact global immunity and prevent further transmission. Vaccines often present commercial viability challenges due to long, complex development timelines and "capacity to pay" issues in developing countries. While some that achieve global population health success, such as the Human Papillomavirus vaccine, can provide substantial return on investment, ix these trends have meant that, compared to novel therapeutics, far fewer vaccines have made it through clinical testing. As a result, regulators and vaccine developers lack experience in vaccine development comparable to novel therapeutics [13] . This could become increasingly problematic if all current COVID-19 clinical and pre-clinical vaccine candidates are simultaneously vying for regulators' attention and resources to expeditiously review clinical protocols and evidence dossiers. Not to mention disruption to other clinical programs as regulators are re-directed to reviewing the clinical protocols of dozens of COVID-19 vaccine candidates and even more therapeutic candidates. Beyond these bottlenecks, the underlying support required within bioanalytical and pathology providers will also be critical to ensuring rapid availability and interpretation of clinical data.

The changing dynamics of the disease as it continues to emerge could also affect the development of vaccines when trial designs are informed by the epidemiology of the virus.

As governments implement lockdowns and non-essential travel and transmission rates decline, clinical trial recruitment will become challenging across the potentially dozens of J o u r n a l P r e -p r o o f 6 independent clinical programs striving for patients and healthy volunteers. In addition, patient screening for COVID-19-negative status and monitoring of potential virus exposure while on study will create additional challenges and opportunities for early trial endpoints.

If regulatory bottlenecks prevent solutions being brought to the public in time to reduce the impact of an epidemic, then we need to consider alternatives that deliver solutions at an earlier stage of an epidemic, in the geographical jurisdictions where the outbreak is occurring. Governments can leverage harmonized regulatory standards, mutual recognition, and regulatory reliance mechanisms to enhance existing regulatory pathways and accelerate and coordinate approvals globally. x This would be particularly beneficial in countries that traditionally suffer submission and approval lags for novel drugs and vaccines.

With the data at hand from previous outbreaks, we can consider predictive epidemiological models that can guide globally coordinated responses ahead of the curve We also need to be better prepared in the areas of pre-clinical science including animal challenge models, clinical trial pathways from safety to efficacy, and for innovative and adaptive clinical trial designs such as umbrella studies (where multiple candidates are tested under a single protocol) to become the norm in times of epidemics. While some of these trial initiatives have started to emerge, such as the SOLIDARITY trial, they are still few and far between. This is especially problematic considering there are currently over 500 randomized controlled-studies for COVID-19 preventatives and treatments, 31 of which have at least two arms and a target sample size of at least 1,000 patients (some with recruitment targets of 40,000-55,000) [14] . Large, randomized and placebo-controlled studies have been associated with longer total development times, as opposed to smaller, non-randomized single-arm or extension-arm studies [8] . Last, guidance documents for pandemic trials should be available in anticipation of pandemics, ready to be triggered as soon as the WHO declares a public health emergency, and remain in effect after the public health crisis has abated. Slanted lines indicate overlap in development milestones; the genomes of MERS and SARS-CoV-2 (COVID-19) were sequenced and diagnostic tests developed before The WHO issued their alert. See Table S1 for dates of featured events. Table S1 for key events). Data sources: SARS: WHO i ; H1N1: WHO ii , FluNet/WHO Global Influenza Surveillance and Response System (GISRS) iii a,b ; MERS: European Centre for Disease Prevention and Control (ECDC) iv ; Ebola: Centers for Disease Control and Prevention (CDC) v ; Zika: Pan American Health Oragnization (PAHO)/WHO vi ; COVID19: Johns Hopkins University vii, c . Notes: a H1N1 data comes from surveillance of global circulation of influenza viruses; b Number of specimens positive for H1N1 reported to GISRS; c COVID-19 cases for month 4 are from 1st April 2020 to 27th April 2020.

A new twenty-first century science for effective epidemic response

An interactive web-based dashboard to track COVID-19 in real time

Open access epidemiological data from the COVID-19 outbreak

Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia

Detection of a novel human coronavirus by real-time reversetranscription polymerase chain reaction

Coronavirus outbreak changes how scientists communicate

The COVID-19 vaccine development landscape

Precision medicines have faster approvals based on fewer and smaller trials than other medicines

FDA Approval and Regulation of Pharmaceuticals

The African vaccine regulatory forum (AVAREF): A platform for collaboration in a public health emergency

On a path to accelerate access to Ebola vaccines: The WHO's research and development efforts during the 2014-2016 Ebola epidemic in West Africa

Demonstrating vaccine effectiveness during a waning epidemic: A WHO/NIH meeting report on approaches to development and licensure of Zika vaccine candidates

The pandemic pipeline

Clinical trials for the prevention and treatment of coronavirus disease 2019 (COVID-19): The current state of play

zika-subregions-es&Itemid=353 vii

The authors would like to thank the anonymous reviewer and the